BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Smalls DJ, Kiger RE, Norris LB, Bennett CL, Love BL. Hepatitis B Virus Reactivation: Risk Factors and Current Management Strategies. Pharmacotherapy 2019;39:1190-203. [PMID: 31596963 DOI: 10.1002/phar.2340] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Niu JX, Xu Y, Wu DP. [Progress in the research of HBV reactivation in patients undergoing hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi 2021;42:348-52. [PMID: 33979984 DOI: 10.3760/cma.j.issn.0253-2727.2021.04.016] [Reference Citation Analysis]
2 Krajnc N, Bsteh G, Berger T, Mares J, Hartung HP. Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management. Neurotherapeutics 2022. [PMID: 35378683 DOI: 10.1007/s13311-022-01224-9] [Reference Citation Analysis]
3 Zhang J, Liu X, Zhou W, Cheng G, Wu J, Guo S, Jia S, Liu Y, Li B, Zhang X, Wang M. A bioinformatics investigation into molecular mechanism of Yinzhihuang granules for treating hepatitis B by network pharmacology and molecular docking verification. Sci Rep 2020;10:11448. [PMID: 32651427 DOI: 10.1038/s41598-020-68224-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
4 Ziogas DC, Kostantinou F, Cholongitas E, Anastasopoulou A, Diamantopoulos P, Haanen J, Gogas H. Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy. J Immunother Cancer 2020;8:e000943. [PMID: 33067316 DOI: 10.1136/jitc-2020-000943] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
5 Bedi HK, Chahal D, Lowe CF, Ritchie G, Hussaini T, Marquez V, Yoshida EM. Occult Hepatitis B Reactivation after Liver Transplant: The Role of a Novel Mutation in the Surface Antigen. J Clin Transl Hepatol 2021;9:136-8. [PMID: 33604265 DOI: 10.14218/JCTH.2020.00090] [Reference Citation Analysis]
6 Yamazaki T, Joshita S, Ichijo T, Kobayashi H, Wakabayashi SI, Yamashita Y, Sugiura A, Kawakami F, Nakazawa H, Umemura T. Successful treatment by glecaprevir/pibrentasvir followed by hepatoprotective therapy of acute chronic hepatitis exacerbation caused by daratumumab-based regimen for multiple myeloma: Case report and review of the literature. J Infect Chemother 2021;27:1750-5. [PMID: 34344581 DOI: 10.1016/j.jiac.2021.07.018] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Živković SA, Gruener G, Narayanaswami P; AANEM Quality and Patient Safety Committee. Doctor-Should I get the COVID-19 vaccine? Infection and immunization in individuals with neuromuscular disorders. Muscle Nerve 2021;63:294-303. [PMID: 33471383 DOI: 10.1002/mus.27179] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
8 Librero Jiménez M, López Garrido MÁ, Fernández Cano MC. Letter to the editor: Reactivation of HBV triggered by SARS-CoV-2 in a patient with cirrhosis. Hepatology 2021. [PMID: 34888903 DOI: 10.1002/hep.32271] [Reference Citation Analysis]
9 Onorato L, Pisaturo M, Camaioni C, Grimaldi P, Codella AV, Calò F, Coppola N. Risk and Prevention of Hepatitis B Virus Reactivation during Immunosuppression for Non-Oncological Diseases. J Clin Med 2021;10:5201. [PMID: 34768721 DOI: 10.3390/jcm10215201] [Reference Citation Analysis]
10 Kim W, Kim HJ. Monoclonal Antibody Therapies for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. J Clin Neurol 2020;16:355-68. [PMID: 32657055 DOI: 10.3988/jcn.2020.16.3.355] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
11 Godbert B, Petitpain N, Lopez A, Nisse YE, Gillet P. Hepatitis B reactivation and immune check point inhibitors. Dig Liver Dis 2021;53:452-5. [PMID: 32921602 DOI: 10.1016/j.dld.2020.08.041] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
12 Cao X, Wang Y, Li P, Huang W, Lu X, Lu H. HBV Reactivation During the Treatment of Non-Hodgkin Lymphoma and Management Strategies. Front Oncol 2021;11:685706. [PMID: 34277431 DOI: 10.3389/fonc.2021.685706] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Zhang X, Liang Y, Li X, Wang W, Tong J, Xu Y. Clearance of HBsAg in a patient with familial multiple myeloma after a bortezomib-based regimen combined with anti-HBV drug: A case report. Medicine (Baltimore) 2020;99:e22642. [PMID: 33019490 DOI: 10.1097/MD.0000000000022642] [Reference Citation Analysis]
14 Wu J, Yu Y, Dai Y, Zhang Y, Cheng J, Cui D. Research Progress on the Mechanism of Persistent Low-Level HBsAg Expression in the Serum of Patients with Chronic HBV Infection. Journal of Immunology Research 2022;2022:1-11. [DOI: 10.1155/2022/1372705] [Reference Citation Analysis]
15 Perricone C, Triggianese P, Bartoloni E, Cafaro G, Bonifacio AF, Bursi R, Perricone R, Gerli R. The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J Autoimmun. 2020;111:102468. [PMID: 32317220 DOI: 10.1016/j.jaut.2020.102468] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 30.5] [Reference Citation Analysis]
16 Khemichian S, Kahn J, Terrault NA. Use of Hepatitis B Virus-Positive Organs in Organ Transplantation. Clin Liver Dis 2021;25:841-57. [PMID: 34593157 DOI: 10.1016/j.cld.2021.06.009] [Reference Citation Analysis]
17 Malik A, Aldakheel F, Rabbani S, Alshehri M, Chaudhary AA, Alkholief M, Alshamsan A. LCR based quick detection of hotspot G1896A mutation in patients with different spectrum of hepatitis B. J Infect Public Health 2021;14:651-4. [PMID: 33857724 DOI: 10.1016/j.jiph.2021.01.013] [Reference Citation Analysis]